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Abstract 
Extracellular ATP (eATP) activates T cells by engaging the P2X7R receptor. We identified two loss-of-
function P2X7R mutations that are protective against type 1 diabetes (T1D) and thus hypothesized that 
eATP/P2X7R signaling may represent an early step in T1D onset. Specifically, we observed that in 
newly diagnosed T1D patients, P2X7R is upregulated on CD8
+ 
effector T cells in comparison to healthy 
controls. eATP is released at high levels by human/murine islets in vitro in high-glucose/inflammatory 
conditions, thus upregulating P2X7R on CD8
+ 
T cells in vitro. P2X7R blockade with oxidized ATP 
(oATP) reduces the CD8
+ 
T cell-mediated
 
autoimmune response in vitro and delays diabetes onset in 
NOD mice. Autoreactive CD8
+ 
T cell activation is highly dependent upon eATP/P2X7R-mediated 
priming, while a novel sP2X7R recombinant protein abrogates changes in metabolism and the 
autoimmune response associated with CD8
+
 T cells. eATP/P2X7R signaling facilitates the onset of 
autoimmune T1D by fueling autoreactive CD8
+
 cells and therefore represents a novel targeted 
therapeutic for the disorder. 
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Introduction 
Understanding of the immunological mechanisms underlying type 1 diabetes (T1D) development has 
broadened dramatically
1,2
, which has aided in design of potential immunoregulatory treatments capable 
of preventing and/or curing the disease
3,4
. A key goal of these approaches is to revert hyperglycemia in 
T1D patients or to prevent the onset of disease in individuals at high-risk
5
. However, despite much 
effort, an immune-based cure for T1D does not exist, and concern remains due to the increased risk of 
mortality associated with the disorder
6
. Reversal of diabetes can currently be obtained only with 
pancreatic islet
7,8
 or whole pancreas transplantation, which confers a different set of complications and 
sub-optimal long-term outcomes
9
.  
The purine adenosine 5'-triphosphate (ATP) is a small molecule
10
 present in high concentrations within 
cells that can be released into the extracellular compartment as extracellular ATP (eATP) by damaged or 
necrotic cells
11
 and by activated immune cells
12,13
. Once in the extracellular space, eATP can be sensed 
by ionotropic purinergic P2X receptors (7 receptors named P2X1-P2X7 receptors, or P2XRs)
14-16
 as a 
fundamental step in immune cell activation
17-20
. In particular, P2X7R
12,16,21,22
 has been linked to T cell 
activation, serving as a signal amplification mechanism for antigen recognition
17
, Th1/Th17 
generation
1,23
 and allograft rejection
24
. Interestingly, ATP is co-secreted with insulin by pancreatic β 
cells
25,26
. We hypothesize that eATP-driven/P2X7R-mediated immunity may be activated by pancreatic 
β-cell injury (e.g. viruses, stresses), when β cells release eATP and prime passenger leukocytes
25,26
. 
During the autoimmune response, eATP can also be released by cytotoxic T cells, thus creating a 
feedback loop that sustains the autoimmune response and inflammation
1,23,24
. Understanding the 
potential role of the purinergic system in the priming of the T cell-mediated anti-islet immune response 
in the pathogenesis of T1D will contribute to design of potential therapies for T1D, especially 
considering P2X7R inhibitors are available for human use
27,28
.  
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Research Design and Methods 
Genetic studies 
A detailed description of the Joslin Study of Genetics of Kidneys in Diabetes (GoKinD) was recently 
published
1
. Unrelated European-American individuals from the GoKinD (n=3410) and the Exome 
Sequencing Project (ESP6500, n=8600) cohort database were interrogated for P2X7R genetic variants. 
The FREQ Procedure of the SAS system was used to determine the frequency of each single nucleotide 
polymorphism (SNP) of human P2X7R. Odds ratios for each SNP were calculated, and Bonferroni 
correction was applied to each P value. 
Patients 
Blood samples were obtained from new onset diabetic patients, long-term diabetic patients, T2D patients 
and from healthy controls, who were enrolled under an Institutional Review Board committee approval 
(Table 1). Peripheral blood mononuclear cell (PBMC) fractions were isolated
 
from 20 ml whole blood by 
Ficoll density gradient centrifugation.  
Human antibodies 
The following antibodies were used for flow cytometric analysis: phycoerythrin (PE)-Cy7-conjugated 
anti-human CCR7, allophycocyanin (APC)-labeled anti-human CD45RO, Alexa Fluor 700-conjugated 
CD4, V500-conjugated anti-human CD8, APC-labeled anti-human CD11c, and PE-Cy7-conjugated anti-
human CD19 were purchased from BD Biosciences (San Jose, CA), eBioscience (San Diego, CA) or 
Life Technologies (Carlsbad, CA). Fluorescein isothiocyanate (FITC)-conjugated anti-human P2X7R 
was purchased from Alomone Labs (Jerusalem, Israel). 
Human flow cytometric analysis 
To characterize P2X7R expression on T cells, human PBMCs isolated from healthy controls, new onset 
T1D patients, long-standing T1D patients and T2D patients were stained with anti-human CD4, CD8, 
CD11c or CD19 and anti-human P2X7R. Human P2X7R expression on CD4
+
 and CD8
+
 effector and 
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central memory T cells was determined by staining for P2X7R, CD45RO, CCR7 and CD4 or CD8, 
respectively. The number of cells was calculated by acquiring 10
5
 events in the lymphocyte gate (SSC-
FSC) by flow cytometric analysis. 
Intracellular staining for flow cytometry  
Anti-human CD4, CD8, CD25, interferon-γ (IFN-γ) and interleukin-17 (IL-17) were purchased from BD 
Biosciences, Becton-Dickinson (Franklin Lakes, NJ), or Life Technologies, and anti-mouse FITC-
labeled P2X7R was purchased from Alomone Labs. Resting cells were activated with PMA (5 ng/ml), 
ionomycin (500 ng/ml) and brefeldin A (2 µM; Sigma-Aldrich, St. Louis, MO) for 3 h. Cells were 
harvested in FACS tubes and placed on ice. Cells were then washed with FACSFlow (BD Biosciences) 
and processed for intracellular cytokine staining with 0.5% saponin (Sigma-Aldrich) and 2% 
formaldehyde for fixation and permeabilization. Antibodies used for intracellular staining (BD 
Biosciences unless stated otherwise) were PE-conjugated anti-IL-17, and allophycocyanin-conjugated 
anti-IFN-γ. 
 
Human ELISpot assay  
An ELISpot assay was used to measure the number of IFN-γ-producing cells according to the 
manufacturer’s protocol (BD Biosciences) as previously shown by our group
2
. 2x10
6
 PBMCs, isolated 
from T1D patients, were cultured for 48h in the presence of IA-2 (100 µg/ml) peptide. At day 1 after 
stimulation, 500 µl media was added to the culture. Cells were collected at day 2 and plated in a human 
IFN-γ ELISpot assay with or without oATP or CE-224,535 at different concentrations (1, 10 or 100 µM). 
Spots were counted using an A.El.VIS ELISpot Reader (A.EL.VIS GmbH, Hannover, Germany).  
In another assay, we isolated CD8
+
 T cells using microbeads from PBMCs obtained from healthy 
subjects, and 5x10
5
 CD8
+
 T cells were incubated with a mixture of vaccine antigens (Diftavax) (tetanus 
toxoid, difteria, and hemophilus) for 24 hours with/without adding the receptor antagonists oxidized 
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ATP (oATP) or CE-224,535. Using an ELISpot assay, we tested the ability of both P2X7R receptor 
antagonists (oATP or CE-224,535) to halt the activation of CD8
+
 T cells when exposed to vaccination 
antigens. 
Extracellular ATP measurements  
Supernatants were collected from a beta cell line (Beta-lox5, kindly provided by Prof. Clayton Mathews, 
University of Florida), previously cultured and exposed to IFN-γ (2 ng/ml, R&D Systems [Minneapolis, 
MN] +/- IL-1β (1,000 U/ml, Peprotech [Rocky Hill, NJ]) for 3 days to replicate pro-
inflammatory/diabetogenic conditions as previously described
3,4
 under high-glucose conditions (35 mM) 
for eATP quantification. We further compared eATP levels measured in supernatants of beta cells with 
that of other cell lines (Caco-2) and of PBMCs isolated from T1D subjects (2x10
6
 cells/well), cultured in 
the same conditions. Finally, we also collected supernatants from PBMCs of T1D subjects previously 
exposed to IA-2 or Pediacel (Sanofi Pasteur), Diftavax or anti-CD3/CD28 (as described above) to 
quantify eATP. Briefly, supernatant samples were resuspended in ATP assay buffer (300–400 ml) on ice 
and spun at 14,000 g for 5 min at 4°C, after which the supernatant was transferred to a 10 kDa molecular 
weight cutoff spin filter and spun at 14,000 g for 5 min at 4°C to be deproteinized. The samples were 
transferred to a 96-well plate and the fluorescence (lex = 535 nm, lem = 587 nm) was measured using a 
SpectraMax Paradigm Multi-Mode Detection Platform (Molecular Devices, Sunnyvale, CA). The 
background was subtracted from the measurement, and the amount of ATP present in the samples was 
determined from the standard curve. Results obtained were normalized to the number of cells. 
Mice 
Female BALB/c, NOD/ShiLtJ (NOD) at 4 and 8 weeks of age, female NOD/SCID, BDC2.5 TCR NOD 
(NOD-BDC2.5), NOD.Tcr NY8.3 (8.3-NOD) and NOD-P2X7R knock out at 8 weeks of age were 
obtained from the Jackson Laboratory (Bar Harbor, Maine). Female pmeLUC transgenic mice were 
kindly provided by collaboration with the Danish Center for Genetically Modified Mice represented by 
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Ernst-Martin Fuchtbauer, Department of Molecular Biology Aarhus University. Transgenic mice were 
generated by injection of the pmeLUC DNA construct into B6D2F1/J mouse pronuclei. All mice were 
cared for and used in accordance with institutional guidelines approved by the Harvard Medical School 
Institutional
 
Animal Care and Use Committee. 
Results  
P2X7R loss-of-function mutation protects against T1D  
We first analyzed unrelated European-American patients from the Genetics of Kidneys in Diabetes 
(GoKinD, n=1705) and the Exome Sequencing Project (ESP6500, n=4300) cohorts, in order to identify 
any associations between P2X7R genetic variants and the T1D condition. The human P2X7R gene is a 
highly polymorphic gene that spans 52 kb and maps to the chromosomal region 12q24.31. Interrogation 
of the GoKinD and ESP6500 databases revealed 8 single nucleotide polymorphisms (SNPs) in the 
human P2X7R gene (Fig. 1A). Among these SNPs, the rs3751143 and rs7958311 point mutations are 
non-synonymous SNPs (nsSNPs) with an alanine substitution for glutamate at amino acid position 496 
(1513A>C, E496A) and an arginine substitution for histidine at position 270 (835G>A, R270H) 
respectively, leading to P2X7R loss-of-function. Both rs3751143 and rs7958311 appeared to be 
protective against the development of T1D (rs3751143: odds ratio [OR]=0.8, p=0.0006; rs7958311: 
OR=0.86, p=0.01, respectively) (Fig. 1A-B), even after a conservative Bonferroni correction.  
Elevated P2X7R
+ 
T cells are evident in newly diagnosed T1D patients and P2X7R inhibitors reduce 
the human autoimmune response in vitro 
In order to understand the role of eATP/P2X7R signaling in T1D, we first analyzed eATP production 
during an autoimmune response in vitro. When PBMCs obtained from new onset T1D patients were 
challenged with the islet peptide IA-2, increased levels of eATP were evident in the supernatants (Fig. 
1C). We then determined the P2X7R expression profile of different lymphocyte subpopulations in 
PBMCs obtained from patients with newly diagnosed and long-standing T1D as well as healthy controls 
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and T2D patients (Fig. 1D-S; Supplementary Fig. S1A). A higher number of P2X7R
+
CD4
+
 (Fig. 1D-E), 
P2X7R
+
CD4
+
CD45RO
+
CCR7
+
 effector memory T cells (Fig. 1F-G), P2X7R
+
CD8
+
 (Fig. 1L-M) were 
evident in long-standing T1D patients as compared to healthy controls, T2D patients and newly 
diagnosed T1D patients.  Increased numbers of P2X7R
+
CD4
+
CD45RO
+
CCR7
-
 central memory T cells 
(although not statistically significant) (Fig. 1H-I), of P2X7R
+
CD8
+
CD45RO
+
CCR7
+
 effector memory 
(Fig. 1N-O) and P2X7R
+
CD8
+
CD45RO
+
CCR7
-
 central memory T cells (Fig. 1P-Q) were observed in 
newly diagnosed T1D patients as compared to healthy controls, T2D patients and long-standing T1D 
patients. While there was no difference in the numbers of P2X7R
+
CD19
+
 cells (Fig. 1J-K) between 
groups, increased numbers of P2X7R
+
CD11c
+
 cells (although not statistically significant) (Fig. 1R-S) 
were observed in newly diagnosed and long-standing T1D patients as compared to healthy controls and 
T2D patients. We further observed reduced expression of P2X7R
+
CD4
+
CD45RO
+
CCR7
-
 central 
memory T cells (although not statistically significant) (Fig. 1H-I) and a significant reduction in the 
expression of P2X7R
+
CD8
+
CD45RO
+
CCR7
+
 effector memory T cells (Fig. 1N-O) in T2D patients as 
compared to all other groups. To evaluate the benefit of targeting the eATP/P2X7R axis during the 
autoimmune response, two P2X7R inhibitors, oxidized ATP (oATP) and CE-224,535, were used in 
human autoimmune assays in vitro. In a 24-hour ELISpot assay, the T cell response against the islet 
peptide IA-2, measured as number of IFN-γ-producing cells, was reduced by the addition of the P2X7R 
inhibitors oATP and CE-224,535 (Fig. 1T).  
Human CD8
+ 
cell function appears highly linked to eATP/P2X7R-signaling during the autoimmune 
response  
To further delineate the role of eATP/P2X7R signaling in CD4
+
 and CD8
+
 naïve T cells, we cultured 
CD4
+
CD25
-
 and CD8
+
 T cells in the presence of IA-2 and measured the percentage of IFN-γ
+
 and IL-17
+
 
cells generated during an autoimmune response by flow cytometry. The CD4 T cell-associated 
autoimmune response appeared to be primarily mediated by IFN-γ
+
 cells, with few IL-17
+
 cells being 
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generated (Fig. 1U-V); in fact, in both cases cytokines appeared to be predominantly produced by the 
CD4
+
CD25
-
P2X7R
-
 subpopulation and thus appeared independent of eATP/P2X7R signaling (Fig. 1U-
V). In contrast, the CD8
+
 cell autoimmune response was mostly associated with IL-17 production, 
principally from the P2X7R
+
CD8
+
 subpopulation, and therefore was strictly dependent upon 
eATP/P2X7R signaling (Fig. 1W-X).  
eATP is highly released by human/murine pancreatic islets in vitro during high-glucose/inflammatory 
conditions 
We then explored the ability of pancreatic islets to release eATP in response to various stimuli. First, 
pancreatic eATP release was evaluated in vitro during challenge with high glucose and with pro-
inflammatory cytokines. Pancreata were harvested from pmeLUC transgenic mice, which express 
luciferase on their cell membrane, and were cultured in the presence of different glucose concentrations. 
Luminescence was monitored at different time points during high-glucose challenge using an IVIS-
Caliper luminometer (Fig. 2A). In this assay, the levels of bioluminescence observed are proportional to 
eATP concentration
29
. An increase in the extent of luminescence dependent on glucose level was evident 
(Fig. 2A-B, Supplementary Fig. S1B). We then purified islets from 10-week-old NOD/SCID mice and 
from deceased human donors and cultured them with either (i) normal glucose (control), (ii) a cocktail of 
cytokines composed of IL-1β, TNF-α and IFN-γ (known to be involved in islet damage) or (iii) high 
glucose (HG, 25mM) (Fig. 2C-D). Both the cytokine cocktail and high-glucose conditions increased the 
release of eATP by murine and human pancreatic islets; indeed, the highest eATP release was observed 
following exposure to high glucose (Fig. 2C-D). We next challenged a human β cell line (Beta-lox5) in 
the presence of different stimuli (i.e. high glucose, IFN-γ or IL-1β) and quantified eATP release 
(Supplementary Fig. S1C). The same experiment was performed on a human intestinal Caco-2 cell line 
and on human PBMCs from T1D using all the aforementioned conditions including Diftavax and anti-
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CD3/anti-CD28 stimulation (Supplementary Fig. S1D-E). Beta-lox5 cells released high levels of eATP, 
measured in the culture supernatant, as compared to other cell lines (Supplementary Fig. S1C-E).  
eATP is released by pancreatic islets in vivo during the early phase of diabetes onset in NOD mice 
To assess the in vivo release of eATP from pancreatic islets during the onset of autoimmune diabetes in 
NOD mice, HEK293-pmeLUC transgenic cells and D-luciferin were injected into the peritoneal cavity 
of NOD and BALB/c mice. HEK293-pmeLUC transgenic cells function as reporters of eATP 
concentration in vivo
16
. Please see Research Design and Methods for a description of the system. A 
stable luminescence signal was observed in BALB/c mice at different ages (Fig. 2E-F), while in NOD 
mice, the luminescence signal appeared higher than that which was obtained in BALB/c mice (Fig. 2E-
F). A gradual disappearance of bioluminescence was evident over time in NOD mice, paralleling 
insulitis progression and the autoimmune-mediated destruction of pancreatic islets (Fig. 2E-F). The area 
under the curve (AUC) of bioluminescence confirmed the increased eATP release in NOD mice as 
compared to BALB/c mice over time (Fig. 2G). Peripheral serum levels of eATP were then measured 
and were confirmed to be highest in 4-week-old NOD mice (Fig. 2H). 
T cells release eATP during an autoimmune response in vitro and eATP stimulates P2X7R expression 
on T cells 
We then assessed eATP release during an autoimmune response in vitro by incubating splenocytes from 
hyperglycemic NOD mice for 24 hours in the presence of different islet-derived peptides (BDC2.5, 
IGRP, GAD65 and insulin) in an ELISpot assay (Fig. 2I). eATP levels in the supernatant were increased 
during the autoimmune response against islet peptides and were observed to be highest following 
stimulation with the CD8-restricted peptide IGRP (Fig. 2I, red line). Interestingly, eATP levels 
paralleled the number of IFN-γ
+
 T cells generated during the autoimmune response (Fig. 2I, bar graph). 
To evaluate the effect of eATP on P2X7R expression in naïve T cells in in vitro studies, we used 
BzATP, a prototypic P2X7R agonist that exhibits 5- to 10-fold greater potency than ATP. CD4
+
CD25
-
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and CD8
+
 T cells, isolated from normoglycemic NOD mice, were cultured for 24 hours in the presence 
of varying concentrations of activating cytokines, such as IL-1β, IL-6, TNF-α, MCP-1, ATP or BzATP, 
with P2X7R expression then quantified by flow cytometry. Almost all cytokines induced a slight but 
significant upregulation of P2X7R expression on CD4
+
CD25
-
 T cells as compared to medium alone; in 
addition, a 3-fold increase in P2X7R expression was evident when culturing CD4
+
CD25
-
 T cells with 
BzATP and ATP (Fig. 2J; Supplementary Fig. S2G). While no cytokines induced a significant increase 
in P2X7R expression in CD8
+
 T cells, ATP and BzATP at its highest concentration significantly induced 
an increase in P2X7R expression as compared to medium alone (Fig. 2K; Supplementary Fig. S2H). It is 
likely that inflammation triggered by cytokines vs. cell necrosis involve two different pathways, such 
that only inflammation due to cell necrosis is eATP/P2X7R-dependent. 
P2X7R
+ 
T cells increase in vivo and in vitro during the murine autoimmune response 
Flow cytometric analysis of splenic CD4
+ 
and CD8
+
 T cells in NOD mice revealed an increased 
percentage of P2X7R
+
CD4
+
 T cells, P2X7R
+
CD4
+
 effector T cells and particularly P2X7R
+
CD8
+ 
T cells 
and P2X7R
+
CD8
+ 
effector T cells, both in 4- and partially in 10-week-old NOD mice as compared to 
hyperglycemic NOD mice (Fig. 2L-O). Conversely, the percentage of P2X7R
+ 
CD4
+
CD25
+
Foxp3
+
 
regulatory T cells (Tregs) was significantly increased in hyperglycemic NOD mice as compared to other 
groups (Fig. 2P). This observation led us to investigate the function of P2X7R
pos
 and
 
P2X7R
neg
 Tregs. 
We thus compared the ability of P2X7R
pos
 and
 
P2X7R
neg
 Tregs to suppress the autoimmune response 
generated by diabetogenic T cells isolated from NOD BDC2.5 mice and stimulated with BDC2.5 
peptide. P2X7R
pos
 Tregs showed impaired suppressive function (Supplementary Fig. S5A-B), reduced 
metabolic activity and lower oxygen consumption rates (OCR) as compared to P2X7R
neg
 Tregs 
(Supplementary Fig. S5D-E). Moreover, P2X7R
pos 
Tregs produced more pro-inflammatory cytokines 
(i.e. IFN-γ and IL-17) compared to P2X7R
neg
 Tregs (Supplementary Fig. S5C). P2X7R stimulation with 
BzATP during Treg generation also induced a decrease in the percentage of newly generated Tregs and 
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an overall reduction in FoxP3 expression (Supplementary Fig. S5F-H). Interestingly, P2X7R signaling 
with BzATP increased the production of proinflammatory cytokines (Supplementary Fig. S5I) as well as 
the percentage of apoptotic cells (Supplementary Fig. S5G). 
When isolated CD4
+
CD25
-
 and CD8
+
 T cells were cultured for 24 hours in the presence of 
BDC2.5/IGRP peptides and CD11c
+
 cells, a significant increase in P2X7R
+
 cells, particularly in those 
that were CD8
+
, was evident (Fig. 2Q-R). Interestingly, islets from 4-week-old NOD mice showed 
preserved architecture and scanty T cell infiltrate with very few P2X7R
+
 cells, while islets from 10-
week-old and Hglc NOD exhibited substantial CD3
+
 T cell infiltrate, which appeared to be 
predominantly P2X7R
+
 (Fig. 3A-B and Supplementary Fig. S2A-B). We then evaluated the expression 
of P2XsR mRNA in the whole pancreas and in CD4
+
CD25
-
 and CD8
+
 T cells obtained from spleen of 
NOD mice at different ages. P2X1R and P2X7R mRNA expression appeared highest among P2X 
receptors in the pancreas of NOD mice in the early phase of the disease and decreased following islet 
infiltration and insulitis (Fig. 3C). Conversely, mRNA P2X expression in splenic CD4
+
CD25
-
 and CD8
+
 
T cells is broader and more diverse (Supplementary Fig. S2C-D). These data suggest that islet 
inflammation and damage that occurred during the autoimmune response contributes to the engagement 
of ATP/P2X7R immunity by stimulating P2X7R expression on T cells and thus creating a 
proinflammatory environment through generation of a pool of highly activated T cells committed to the 
Th1/Th17 lineage, which thus facilitates T1D onset. 
Targeting the eATP/P2X7R axis in vitro reduced T cell P2X7R expression as well as the CD8
+
 T cell-
dependent autoimmune response 
To evaluate whether targeting of eATP/P2X7R-driven immunity had any effect on the expression of 
P2X7R, isolated CD4
+
CD25
-
 and CD8
+
 T cells were cultured for 24 hours with different anti-cytokine 
monoclonal antibodies (mAbs) (i.e. anti-IFN-γ, anti-IL-4 or anti-IL-17) or with P2X7R inhibitors (oATP 
and CE-224,535). Compared to baseline, CE-224,535, but not oATP, significantly reduced P2X7R 
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expression on both CD4
+
CD25
-
 and CD8
+
 T cells (Fig. 3D-E). A slight decrease was also observed in 
CD4
+
CD25
-
 T cells cultured with anti-IFN-γ mAb (Fig. 3D) and in CD8
+
 T cells cultured with anti-IL-
17 mAb (Fig. 3E). To test the effect of blocking eATP/P2X7R-driven immunity during an autoimmune 
response, we cultured splenocytes from hyperglycemic NOD mice with BDC2.5, IGRP, GAD65, and 
insulin peptides for 24 hours in the presence of different concentrations of oATP (1, 10, 100µM) in an 
ELISpot assay. Blocking the eATP/P2X7R axis reduced the production of IFN-γ by T cells in this 
autoimmune assay (Fig. 3F). Interestingly, the effect was specific to P2X7R, as the P2X1R inhibitor 
NF449 and the P2X4R inhibitor 5-BDBD were ineffective or induced IFN-γ production by T cells, 
respectively (Fig. 3G-H). We then cultured isolated CD4
+
CD25
-
 and CD8
+
 T cells in the same islet 
peptide-based ELISpot assay in the presence of different concentrations of oATP or CE-224,535, with 
islet peptides and CD11c
+ 
cells to present antigen. oATP, but not CE-224,535, reduced the production of 
IFN-γ by CD8
+
 T cells (Fig. 3K-L) but not by CD4
+
CD25
-
 T cells (Fig. 3I-J) following stimulation with 
IGRP or BDC2.5 peptides, respectively. Interestingly, in the same aforementioned autoimmune assay, 
BzATP significantly reduced the number of IFN-γ
+
 T cells by inducing T cell apoptosis when used at 
higher concentrations (Supplementary Fig. S2E-F). In order to understand the effect of P2X7R targeting 
on a broader CD8
+
-restricted immune response, CD8
+
 T lymphocytes isolated from peripheral blood of 
healthy control individuals were incubated with a mixture of vaccine antigens (Diftavax) for 24 hours in 
the presence or absence of P2X7R antagonists (oATP or CE224,535). The number of IFN-γ-producing 
CD8
+ 
cells was significantly reduced after addition of both antagonists, reaffirming the effect of P2X7R 
targeting on CD8 activation (Supplementary Fig. S1F). 
Targeting the eATP/P2X7R axis delays diabetes onset in NOD mice in vivo 
We then tested the effect of targeting the eATP/P2X7R axis in NOD mice in vivo in early and late 
prevention of diabetes as well as in reversal studies, using (i) oATP, (ii) CE-224,535, and (iii) a 
combination of oATP or CE-224,535 with clinical-grade-dose Rapamycin. A significant delay in 
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diabetes onset in early prevention studies was observed in NOD mice treated with oATP or the 
combination of oATP and Rapamycin, but not in untreated controls or those treated with CE-224,535 
alone or in combination with Rapamycin (Fig. 4A-D). In late prevention studies, both oATP and CE-
224,535 successfully delayed diabetes onset when used in combination with Rapamycin but not when 
used alone (Fig. 4E-H). Treatment with Rapamycin alone did not show any effect on diabetes onset in 
either early or late prevention studies. In reversal studies, NOD mice treated with oATP alone, 
Rapamycin alone, or the combination of CE-224,535 and Rapamycin remained hyperglycemic 
(Supplementary Fig. S3A-E). The combination of oATP and Rapamycin or CE-224,535 alone resulted in 
2 out of 5 mice becoming normoglycemic for several days, then reverting to hyperglycemia 
(Supplementary Fig. S3B-C). Rapamycin alone did not reverse hyperglycemia in NOD mice 
(Supplementary Fig. S3E). Histopathological analysis of 4-week-old NOD mice treated with oATP alone 
or in combination with Rapamycin demonstrated better preserved islet architecture and insulin staining 
as compared to untreated 4-week-old NOD mice (Fig. 4I). Diminished lymphoid infiltration was 
observed in the islets of mice treated with the combination of oATP plus Rapamycin as indicated by 
staining for the T cell marker CD3 when compared to both control animals and mice treated with oATP 
alone (Fig. 4I: 4-6). Semi-quantitative analysis confirmed the diminished islet infiltrate (Fig. 4K) despite 
a slight reduction in the number of islets of Langerhans in mice treated with either oATP alone or oATP 
and Rapamycin. The aforementioned effect may be related to Rapamycin, which has been reported to be 
capable of impairing islet cell function (Fig. 4L). Amelioration of islet architecture and of preserved 
insulin staining was also observed in 10-week-old NOD mice treated with the combination of oATP and 
Rapamycin in comparison to untreated and oATP-treated mice, despite the presence of lymphoid 
infiltrate (Fig. 4J). Thus, targeting the eATP/P2X7R axis delays diabetes onset in the early stages of the 
disease but does not revert established autoimmune diabetes, possibly because in the earlier disease 
stages, due to mild infiltration and greater available  β cell mass, higher release of eATP by the islets 
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plays a role (Fig. 4A-D). At later stages of the disease, loss of β cell mass contributes to a decline in 
eATP release, which could explain the lack of effect when using eATP/P2X7R blocking agents (Fig. 4E-
H). We then performed a series of autoimmune in vitro assays to mimic the onset of autoimmune 
diabetes observed in NOD mice. CD4
+
CD25
-
 and CD8
+
 T cells thus were isolated from the spleens of 
NOD mice untreated or treated with oATP alone or in combination with Rapamycin, and cultured in the 
presence of BDC2.5 or IGRP peptides. The number of IFN-γ
+
CD8
+
, but not IFN-γ
+
CD4
+
, T cells was 
reduced in mice treated with oATP alone or in combination with Rapamycin as compared to untreated 
mice, suggesting an effect of P2X7R blockade on the CD8
+
 T cell-dependent autoimmune response only 
(Fig. 4M-N). Interestingly, when studying the P2X7R
-/- 
NOD mouse, which is not protected against 
autoimmune diabetes
30
, we observed substantial mRNA expression of P2X7R, while western blot 
analysis confirmed the absence of P2X7R expression on CD4
+
CD25
-
 and CD8
+
 T cells (Fig. 4Q, S). 
Upregulation of other P2XRs expression on T cells was also evident (Fig. 4O-S). We then examined 
expression of CD38, a cyclic ADP ribose hydrolase that when absent in the NOD mouse, rapidly 
accelerates onset of hyperglycemia. Genetic deletion of P2X7R in CD38-deficient NOD mice was 
shown to prevent this rapid T1D onset
30
. Indeed, immunophenotypic expression analysis of splenocytes 
from P2X7R
-/- 
NOD revealed significant upregulation of CD38 expression on CD4
+
 and CD8
+
 T cells as 
compared to WT NOD (Supplementary Fig. S4A-D).  
Characterization of P2X7R
neg
 and P2X7R
pos
 T cells  
In order to further explore the role of the eATP/P2X7R pathway in T1D onset, we characterized 
P2X7R
neg
 and P2X7R
pos
 cells for migratory ability, autoimmune response and metabolic profile. 
Surprisingly, in NOD mice, T cells expressed a significant amount of intracellular P2X7R, which may 
serve as a P2X7R reservoir (Fig. 5A-D). Among CD4
+
CD25
-
 T cells, those that were P2X7R
neg
 seemed 
to display enhanced migratory ability in response to SDF-1 as compared to P2X7R
pos
 (Fig. 5E). The 
opposite effect was observed in CD8
+
 T cells; those that were P2X7R
pos
 showed a significantly greater 
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migratory ability as compared to P2X7R
neg
 (Fig. 5F), suggesting a differential impact of P2X7R 
signaling on CD4 and CD8 T cell migration ability. Moreover, P2X7R
pos
 CD4
+
CD25
-
 T cells and 
P2X7R
pos
 CD8
+
 T cells showed a significantly greater autoimmune response compared to P2X7R
neg
 
CD4
+
CD25
-
 T cells and P2X7R
neg
 CD8
+
 T cells, as demonstrated by a substantially greater number of 
IFN-γ
+
 T cells generated by P2X7R
pos
 CD4
+
CD25
-
 T cells and P2X7R
pos
 CD8
+
 T cells during an islet 
peptide-based ELISpot assay (Fig. 5G-H). In addition, metabolic profiles were significantly altered 
between P2X7R
pos
 CD4
+
CD25
-
 T cells, P2X7R
pos
 CD8
+ 
T cells, and their P2X7R
neg 
counterparts. Upon 
examination of bioenergetic changes in the aforementioned four populations, the oxygen consumption 
rate (OCR), an indicator of oxidative phosphorylation (OXPHOS), was significantly decreased in the 
basal state in P2X7R
pos
 CD4
+
CD25
-
 T cells when compared to P2X7R
neg
 CD4
+
CD25
-
T cells and 
P2X7R
pos
 CD8
+
 T cells
 
(Fig. 5I-L). P2X7R
pos
 CD4
+
 T cells showed significantly reduced maximal 
respiration in response to the uncoupling agent FCCP, as compared to P2X7R
neg
 CD4
+
 T cells (Fig. 5I-J). 
While P2X7R
pos
 CD8
+
 T cells appeared hypermetabolic given that they showed significantly higher 
maximal respiration in response to the uncoupling agent FCCP, OCR values significantly increased in 
response to oligomycin (ATP synthase inhibitor), and to rotenone (complex I inhibitor) and antimycin A 
(complex III inhibitor), (Fig. 5J, L). The latter suggests differential behavior when mitochondrial 
respiration is augmented as spare respiratory capacity (SRC) increased in P2X7R
pos
 CD8
+
 T cells in 
comparison to their P2X7R
neg
 counterparts (Fig. 5J, L). We have extended our investigation to assess the 
glycolytic capacity of P2X7R
neg
 and P2X7R
pos
 CD8
+
 T cells. P2X7R
neg
 CD8
+
 T cells did not display a 
robust glycolytic response when exposed to glucose or oligomycin (Supplementary Fig. S3F-G) and 
therefore exhibited reduced glucose uptake, while P2X7R
pos
 CD8
+
 T cells displayed an increased 
glycolytic reserve, likely to enhance their activity during an autoimmune response (Supplementary Fig. 
S3F-G). 
We then characterized P2X7R
neg
 and P2X7R
pos
 cells within CD4
+
 T cells from NOD.BDC2.5 mice and 
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CD8
+
 T cells from NOD.8.3 mice. Immunophenotypic analysis, examination of migratory properties, 
results of ELISpot assays and bioenergetic profiling confirmed what was observed for WT NOD mice 
(Fig. 5M-X), with minor differences. P2X7R
pos
 CD4
+
CD25
-
 T cells from NOD.BDC2.5 mice exhibited 
higher OCR at basal conditions and in response to FCCP (Fig. 5U,W), as well as higher ATP production 
(Fig. 5W) overall. 
The novel recombinant protein sP2X7R reduces CD8-restricted autoimmune responses 
We generated a recombinant protein based on the 595-amino-acid P2X7R extracellular domain 
(sP2X7R) (Fig. 6A-C), thus offering a novel therapeutic option able to quench eATP (Video S1). The 
addition of sP2X7R to an anti-islet peptide-based ELISpot reduced the number of IFN-γ
+
 CD8
+
, but not 
of CD4
+
, T cells from NOD mice (Fig. 6D-E). The same effect was observed when using transgenic 
CD8
+
/CD4
+
 T cells (Fig. 6F-G). CD8
+
 T cells that were cultured with IGRP peptide and sP2X7R 
exhibited higher OCR at basal conditions and in response to FCCP at all time points (Fig. 6H-I). ATP 
production was also higher in cells that were cultured with sP2X7R as compared to CD8
+
 T cells 
cultured with IGRP peptide alone, suggesting interference of our recombinant protein sP2X7R with the 
eATP/P2X7R axis and with the bioenergetic activity of CD8
+ 
T cells (Fig. 6I). We can now propose a 
working hypothesis in which eATP released by β cells during stress/injury mediated by viruses, 
autoantibodies and other factors induces P2X7R expression on T cells (particularly on CD8
+ 
cells) and 
facilitates their activation, leading to T cell priming. Pharmacological targeting of the eATP/P2X7R 
signaling using oATP or the novel recombinant sP2X7R protein prevents the deleterious signaling that 
would be generated outright in CD8
+
 autoreactive T cells, thus delaying the onset of diabetes (Fig. 6J).  
 
Discussion 
The emerging role of eATP as an initiator of the immune response, aside from its metabolic function, has 
been the focus of intense investigation
1,24
. eATP levels can increase as a consequence of release from 
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damaged cells or by activated immune cells and can be sensed by P2X7R
1,24
, which is expressed on T 
cells, thereby triggering their activation. Our initial observation, described herein, that two P2X7R loss-
of-function non-synonymous SNPs appear to be protective against T1D prompted us to hypothesize that 
eATP/P2X7R signaling may be involved in the onset of T1D, despite the lack of protection observed in 
P2X7R
-/-
 NOD mice. To this end, we reported an upregulation of CD38 and of other P2XsR on T cells 
from P2X7R
-/-
 NOD, which may explain why the incidence of T1D was not altered by genetic deletion 
of P2X7R. In fact, lack of CD38 may impair calcium mobilization and immune function, while 
accelerating T1D onset in NOD mice, whereas lack of P2X7R may counteract this effect and stabilize 
calcium efflux and prevent the acceleration of T1D onset. Notably, the “rs7958311” loss-of-function 
mutation was shown to be associated with insulin resistance and impaired glucose tolerance in a cohort 
of T2D patients
31
. Because eATP is secreted with insulin
25,26
, we also hypothesize that β cells may 
participate in their own demise by secreting eATP as a consequence of injury and thus may activate 
leukocytes in an initial step of the T cell-mediated anti-islet autoimmune response. ATP release is not 
restricted to leukocytes, as it has been described that eATP is also secreted by platelet-dense granules, 
therefore providing a positive feedback mechanism
32
. It is possible that this pathway that potentiates 
platelet activation through nucleotide receptors (P2X1, P2Y1 and P2Y12) expressed on the platelet 
surface may be affected as well
32
.  
Phenotypic analysis of P2X7R expression on different T cell populations in the periphery of patients 
with newly diagnosed T1D revealed many perturbations of the P2X7R-related phenotype. Interestingly, 
we demonstrated that during an autoimmune response in vitro, eATP is released in high amounts and 
that this release may upregulate P2X7R on T cells (particularly on CD8
+
 cells), thus creating a vicious 
cycle that sustains the autoimmune response and making P2X7R an attractive target in T1D. Pancreatic 
islets exposed to high glucose or to inflammatory cytokines increasingly released eATP as well; these 
conditions are found frequently in pre-diabetes. Peripheral levels of eATP are increased in the early 
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phase of T1D onset in NOD mice, and similarly, P2X7R expression is increased on CD8
+
 T cells. Most, 
if not all, of the T cells infiltrating the pancreas in NOD mice appeared to be P2X7R
+
, and P2X7R 
mRNA was increased in the pancreata of NOD mice. Of note, P2X7R blockade was effective in 
reducing CD8-restricted, but not CD4-restricted, autoimmune responses in vitro. Targeting of eATP-
P2X7R-driven immunity with oATP delayed diabetes onset in early prevention studies in NOD mice in 
vivo, with pathology confirming reduced lymphoid infiltrate and preserved insulin staining in treated 
NOD mice. Characterization of the P2X7R
neg
 and P2X7R
pos
 cellular compartments revealed that 
CD8
+
P2X7R
+
 T cells migrate more efficiently and produce more IFN-γ/IL-17 when challenged with islet 
peptides as compared to CD8
+
P2X7R
neg
 T cells and, generally, as compared to CD4
+
CD25
-
 cells. The 
bioenergetic profiles of P2X7R
neg
 or P2X7R
pos
 CD4
+
CD25
-
 and CD8
+
 T cells were significantly 
different. Although it has been reported that non-obese diabetic (NOD) mice develop an aggressive T 
cell-mediated destruction of β cells with limited similarity to human disease and also show poor 
predictive value in screening for effective intervention therapies for T1D, the NOD mouse remains the 
most reliable T1D model, as it shares many genetic and physio-pathological features with human T1D
33
. 
The secretion of eATP and insulin constitute, per se, a potential driving force for T cell activation. Any 
perturbation of insulin secretion, or any overexertion by or stress of β cells, may favor increased release 
of eATP, which in turn may activate passenger leukocytes. Viral infection and endoplasmic reticulum 
stress may result in perturbation of the eATP-releasing machinery within β cells as well. Second, it 
appears that autoreactive CD8
+
 T cells are more prone to be affected by and possibly more dependent 
upon eATP/P2X7R signaling as compared to autoreactive CD4
+
 T cells. Third and finally, the novel 
recombinant protein sP2X7R, which we created and produced based on the extracellular domain of 
P2X7R, reduced CD8
+
 T cell activity and autoimmune responses and thus may represent a novel 
therapeutic tool for the prevention of T1D. In conclusion, eATP/P2X7R signaling facilitates the onset of 
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autoimmune diabetes by fueling autoreactive CD8
+
 cells and may represent a novel therapeutic target for 
T1D. 
 
Author contributions  
S.T. designed and performed experiments, analyzed data, and wrote the paper; C.F. and A.P. designed 
and performed research, analyzed the data, and edited the paper; M.BN., A.V., F.D, V.U., S.F., R.B., 
S.D., C.R., A.M., E.F. performed experiments and analyzed data; A.S., D.C., E.G., C.M., F.B., M.G.P., 
C.H.W. helped with sample collection, pathology and analysis of data; C.R., F.F., F.D.V., S.D., A.P. 
G.V.Z., C.W., M.AA. coordinated research; P.F. conceived the study, designed research, wrote and 
edited the paper. All authors reviewed and edited the paper. 
 
Acknowledgments 
Paolo Fiorina is the recipient of an EFSD/Sanofi European Research Programme and is supported by an 
American Heart Association (AHA) Grant-in-Aid. We thank the Fondazione Romeo and Enrica 
Invernizzi for their generous support. 
Dr. Paolo Fiorina is the guarantor of this work and, as such, had full access to all the data in the study 
and takes responsibility for the integrity of the data and the accuracy of the data analysis. 
 
Disclaimer 
This article was prepared while Dr. Pileggi was employed at the University of Miami. He is currently 
employed at the Center for Scientific Review of the National Institutes of Health. The opinions 
expressed in this article are the author's own and do not necessarily reflect the views of the National 
Institutes of Health, the Department of Health and Human Services, or the United States government. 
 
Page 21 of 62 Diabetes
21 
 
Disclosure 
The authors have nothing to disclose. 
 
References  
1. Vergani A, Tezza S, D'Addio F, et al. Long-term heart transplant survival by targeting the 
ionotropic purinergic receptor P2X7. Circulation 2013;127:463-75. 
2. Guleria I, Gubbels Bupp M, Dada S, et al. Mechanisms of PDL1-mediated regulation of 
autoimmune diabetes. Clin Immunol 2007;125:16-25. 
3. McClymont SA, Putnam AL, Lee MR, et al. Plasticity of human regulatory T cells in healthy 
subjects and patients with type 1 diabetes. J Immunol 2011;186:3918-26. 
4. Fiorina P, Jurewicz M, Vergani A, et al. Targeting the CXCR4-CXCL12 axis mobilizes 
autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1. 
J Immunol 2011;186:121-31. 
5. Naserke HE, Bonifacio E, Ziegler AG. Prevalence, characteristics and diabetes risk associated 
with transient maternally acquired islet antibodies and persistent islet antibodies in offspring of parents 
with type 1 diabetes. J Clin Endocrinol Metab 2001;86:4826-33. 
6. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 
diabetes. N Engl J Med 2014;371:1972-82. 
7. Fiorina P, Shapiro AM, Ricordi C, Secchi A. The clinical impact of islet transplantation. Am J 
Transplant 2008;8:1990-7. 
8. D'Addio F, Maffi P, Vezzulli P, et al. Islet transplantation stabilizes hemostatic abnormalities and 
cerebral metabolism in individuals with type 1 diabetes. Diabetes Care 2014;37:267-76. 
9. Fiorina P, Secchi A. Pancreatic islet cell transplant for treatment of diabetes. Endocrinol Metab 
Clin North Am 2007;36:999-1013; ix. 
Page 22 of 62Diabetes
22 
 
10. Novak I. ATP as a signaling molecule: the exocrine focus. News Physiol Sci 2003;18:12-7. 
11. Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a 
find-me signal to promote phagocytic clearance. Nature 2009;461:282-6. 
12. Schenk U, Westendorf AM, Radaelli E, et al. Purinergic control of T cell activation by ATP 
released through pannexin-1 hemichannels. Sci Signal 2008;1:ra6. 
13. Piccini A, Carta S, Tassi S, Lasiglie D, Fossati G, Rubartelli A. ATP is released by monocytes 
stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an 
autocrine way. Proc Natl Acad Sci U S A 2008;105:8067-72. 
14. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998;50:413-92. 
15. Khakh BS, North RA. P2X receptors as cell-surface ATP sensors in health and disease. Nature 
2006;442:527-32. 
16. Wilhelm K, Ganesan J, Muller T, et al. Graft-versus-host disease is enhanced by extracellular 
ATP activating P2X7R. Nat Med 2010;16:1434-8. 
17. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 
2011;11:201-12. 
18. Casati A, Frascoli M, Traggiai E, Proietti M, Schenk U, Grassi F. Cell-autonomous regulation of 
hematopoietic stem cell cycling activity by ATP. Cell Death Differ 2011;18:396-404. 
19. Gabel CA. P2 purinergic receptor modulation of cytokine production. Purinergic Signal 
2007;3:27-38. 
20. Atarashi K, Nishimura J, Shima T, et al. ATP drives lamina propria T(H)17 cell differentiation. 
Nature 2008;455:808-12. 
21. Yip L, Woehrle T, Corriden R, et al. Autocrine regulation of T-cell activation by ATP release and 
P2X7 receptors. FASEB J 2009;23:1685-93. 
Page 23 of 62 Diabetes
23 
 
22. Ferrari D, Pizzirani C, Adinolfi E, et al. The P2X7 receptor: a key player in IL-1 processing and 
release. J Immunol 2006;176:3877-83. 
23. Vergani A, Fotino C, D'Addio F, et al. Effect of the purinergic inhibitor oxidized ATP in a model 
of islet allograft rejection. Diabetes 2013;62:1665-75. 
24. Vergani A, Tezza S, Fotino C, et al. The Purinergic System in Allotransplantation. Am J 
Transplant 2014. 
25. Richards-Williams C, Contreras JL, Berecek KH, Schwiebert EM. Extracellular ATP and zinc 
are co-secreted with insulin and activate multiple P2X purinergic receptor channels expressed by islet 
beta-cells to potentiate insulin secretion. Purinergic Signal 2008;4:393-405. 
26. Geisler JC, Corbin KL, Li Q, Feranchak AP, Nunemaker CS, Li C. Vesicular nucleotide 
transporter-mediated ATP release regulates insulin secretion. Endocrinology 2013;154:675-84. 
27. Murgia M, Hanau S, Pizzo P, Rippa M, Di Virgilio F. Oxidized ATP. An irreversible inhibitor of 
the macrophage purinergic P2Z receptor. J Biol Chem 1993;268:8199-203. 
28. Rizzo R, Ferrari D, Melchiorri L, et al. Extracellular ATP acting at the P2X7 receptor inhibits 
secretion of soluble HLA-G from human monocytes. J Immunol 2009;183:4302-11. 
29. Falzoni S, Donvito G, Di Virgilio F. Detecting adenosine triphosphate in the pericellular space. 
Interface Focus 2013;3:20120101. 
30. Chen YG, Scheuplein F, Driver JP, et al. Testing the role of P2X7 receptors in the development 
of type 1 diabetes in nonobese diabetic mice. J Immunol 2011;186:4278-84. 
31. Todd JN, Poon W, Lyssenko V, et al. Variation in glucose homeostasis traits associated with 
P2RX7 polymorphisms in mice and humans. J Clin Endocrinol Metab 2015;100:E688-96. 
32. Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide receptor signaling 
in platelets. J Thromb Haemost 2006;4:2317-26. 
Page 24 of 62Diabetes
24 
 
33. Roep BO, Atkinson M. Animal models have little to teach us about type 1 diabetes: 1. In support 
of this proposal. Diabetologia 2004;47:1650-6. 
 
 
 
TABLE AND FIGURE LEGENDS  
 
Table 1. Baseline demographic characteristics of patients enrolled. Data are expressed as mean ± SEM. 
 
Healthy 
Donors 
(n=10) 
Long-term 
T1D 
 (n=10) 
Newly diagnosed 
T1D 
(n=10) 
T2D 
 (n=5) 
 
P values 
Sex (n) 
Male/Female 
 
4/6 
 
4/6 
 
5/5 
4/1 
 
NS 
Age 
(Years) 
 
42.0 ± 5.0 
 
42.0 ± 12.3 
 
10.2 ± 3.2 57.2 ± 1.7 
 
P<0.001 
Diabetes 
duration 
(Years) 
_
 
 
27.1±8.5 
_
 
3.4 ± 0.9 
 
N/A 
HbA1c (%) 
[mmol/mol] 
5.3 ± 1.0 
[34 ± 10.9] 
8.3 ± 1.1 
[67 ± 12.0] 
12.2 ± 1.4 
[110 ± 14.8] 
6.3 ± 0.2 
      [45.4 ± 2.9] 
P<0.001 
P<0.001 
EIR (UI) 
_
 39.8 ± 10.0 
_
 
_
 N/A 
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Abbreviations. Number (n); SEM (standard error of the mean); T1D (type 1 diabetes); T2D (type 2 
diabetes); HbA1c (%) (glycated hemoglobin A1c %); EIR (exogenous insulin requirement); not 
significant (NS); not applicable (N/A) . 
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Figure 1. The eATP/P2X7R axis plays a role in human T1D onset. (A, B) The human P2X7R SNP 
distribution among the GoKind and ESP6500EA cohorts is shown. Two loss-of-function mutations 
(rs3751143 and rs7958311) appeared to be protective toward the onset of T1D (rs3751143: odds ratio 
[OR]=0.8; rs7958311: OR=0.86) even after a conservative Bonferroni correction. (C) Increased eATP 
release by PBMCs from T1D patients was observed following IA-2 challenge as compared to PBMCs 
alone; Pediacel was used as a positive control. (D-S) Greater numbers of P2X7R
+
CD4
+
 T cells (D-E), 
P2X7R
+
CD4
+
CD45RO
+
CCR7
+
 effector memory T cells (F-G), P2X7R
+
CD8
+
 T cells (L-M) and, to a 
lesser extent, P2X7R
+
CD8
+
CD45RO
+
CCR7
-
 central memory T cells (P-Q) were evident in long-
standing T1D patients as compared to healthy controls, T2D patients and newly diagnosed T1D patients. 
Increased numbers of P2X7R
+
CD4
+
CD45RO
+
CCR7
-
 central memory T cells (H-I), 
P2X7R
+
CD8
+
CD45RO
+
CCR7
+
 effector memory T cells (N-O) and P2X7R
+
CD8
+
CD45RO
+
CCR7
-
 
central memory T cells (P-Q) were observed in newly diagnosed T1D patients as compared to healthy 
controls, T2D patients and long-standing T1D patients, respectively. No difference or only slight 
differences were observed in the numbers of P2X7R
+
CD19
+
 (J-K), and P2X7R
+
CD11c
+
 (R-S) cells 
among groups. (T) oATP and CE-224,535 inhibited the anti-islet immune response following culture of 
PBMCs from new onset T1D patients with the IA-2 peptide; Pediacel was used as a positive control. (U-
X) While within the CD4
+
CD25
-
 T cell population the increased percentage of IFN-γ
+
 and IL-17
+
 cells 
during the autoimmune response to IA-2 peptide was observed in the P2X7R
neg
 subpopulation (U-V), for 
CD8
+
 T cells most IL-17
+
 cells generated during the autoimmune response to IA-2 peptide were within 
the P2X7R
pos
 subpopulation (W-X). Data are expressed as mean±standard error of the mean (SEM). 
Data are representative of at least n=3 samples. *P<0.05; **P<0.01; ***P<0.001. 
Abbreviations. nsSNP (non-synonymous single nucleotide polymorphisms); ESP6500EA (Exome 
Sequencing Project 6500 European American); PBMCs (peripheral blood mononuclear cells); GoKinD 
(Genetics of Kidneys in Diabetes); OR (odds ratio); eATP (extracellular ATP); oATP (oxidized ATP). 
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Figure 2. β cells release eATP during stress. (A, B) A glucose-dependent increase in the extent of 
luminescence (A) was evident in pancreata harvested from pmeLUC transgenic mice, cultured in the 
presence of different glucose concentrations and quantified as photons/seconds/grams of pancreas (B). 
(C) Higher levels of eATP were found in the supernatants of murine islets obtained from 10-week-old 
NOD/SCID mice and cultured in high glucose at different time points as compared to controls. The same 
effect was evident to a lesser extent with a cocktail of cytokines (IL-1β, TNF-α and IFN-γ), with high 
glucose being the more robust inducer of eATP. (D) High-glucose conditions and cytokines (IL-1β, 
TNF-α and IFN-γ) caused release of eATP by human islets cultured for 60 minutes. (E-G) A stable 
luminescence signal, as a proxy for in vivo eATP release, was observed in BALB/c mice injected i.p. 
with HEK293-pmeLUC transgenic cells and D-luciferin at different ages, while in NOD mice the 
luminescence signal appeared higher than in BALB/c mice. A gradual disappearance of bioluminescence 
was evident over time in NOD mice, paralleling the autoimmune-mediated destruction of pancreatic 
islets. (H) Higher levels of eATP in peripheral serum were detected in 4-week-old NOD mice, and in 
hyperglycemic NOD mice to a lesser extent, as compared to 10-week-old NOD mice. (I) During islet 
peptide (BDC2.5, IGRP, GAD65 and insulin) (red line) stimulation of splenocytes from NOD mice, 
IGRP (a CD8-restricted islet peptide) caused the highest release of eATP in the supernatant and the 
highest increase in the number of IFN-γ
+
 cells as compared to controls. BDC2.5, GAD65 and insulin 
peptide stimulation induced an increase in the number of IFN-γ
+
 spots as compared to controls as well, 
but to a lesser extent. (J, K) CD4
+
CD25
-
 T cells cultured in the presence of different concentrations of 
IL-1β, IL-6, TNF-α, MCP-1 or BzATP showed a slight but significant upregulation of P2X7R 
expression on CD4
+
CD25
-
 T cells, while in CD8
+
 T cells, BzATP only was capable of upregulating 
P2X7R expression. (L-P) In 4-week-old NOD mice, the percentages of P2X7R
+ 
on CD4
+
/CD4
+
 effector 
T cells and CD8
+
/CD8
+
 effector T cells were increased as compared to 10-week-old Nglc or >14-week-
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old Hglc NOD mice. P2X7R
+
CD4
+
 effector, P2X7R
+
CD8
+
 and CD8
+
 effector T cells were increased in 
10-week-old mice as compared to hyperglycemic NOD. The percentage of P2X7R
pos
 Tregs was 
increased in hyperglycemic as compared to 4- and 10-week-old NOD mice and in 4- as compared to 10-
week-old NOD mice (Q-R). P2X7R expression was increased in CD8
+
 T cells and in CD4
+
CD25
-
 T 
cells, to a lesser extent, after culture with BDC2.5 and IGRP peptides respectively. (S) Insulitis score in 
4-week-old, 10-week-old and hyperglycemic NOD mice is shown; n=9 sections per group were 
analyzed.  Data are expressed as mean±standard error of the mean (SEM). Data are representative of at 
least n=3 mice. *P<0.05; **P<0.01; ***P<0.001. 
Abbreviations. eATP (extracellular ATP); HG (high glucose); wks (weeks of age); Nglc 
(normoglycemic); Hglc (hyperglycemic); AUC (area under the curve); BzATP (Benzoyl-ATP). 
 
Figure 3. P2X7R
+
 T cells make up the vast majority of pancreas-infiltrating cells, while P2X7R 
blockade reduces the autoimmune response in vitro. (A, B) Islets from 10- and, to a lesser extent, 4-
week-old NOD mice showed CD3
+ 
T cell (green) infiltrate, which appeared to be predominantly P2X7R
+
 
(red). (C) P2X1R, P2X4R and P2X7R mRNA pancreatic expression was evident in 4- and, to a lesser 
extent, 10-week-old NOD mice. (D) Significant downregulation of P2X7R expression on CD4
+
CD25
-
 T 
cells was observed when cells were cultured with anti-IFN-γ or the P2X7R inhibitor CE-224,535 as 
compared to medium alone. (E) P2X7R downregulation was observed on CD8
+ 
T cells cultured with 
anti-IL-17 or CE-224,535 as compared to medium alone. (F) Splenocytes from hyperglycemic NOD 
mice cultured with the CD4/CD8-restricted islet mimotope peptides BDC2.5/IGRP respectively or with 
GAD65 and insulin in the presence of oATP showed a reduction in the number of IFN-γ
+
 T cells as 
compared to controls. (G-H) Splenocytes from hyperglycemic NOD mice cultured with BDC2.5 or 
IGRP peptides in the presence of different concentrations of the P2X1R antagonist NF449 or the P2X4R 
antagonist 5-BDBD did not show any effect or showed an increase in the number of IFN-γ
+
 T cells, 
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respectively. (I-L) oATP, but not CE-224,535, reduced the number of IFN-γ
+
 CD8
+
, but not CD4
+
, T 
cells when CD4
+
CD25
-
 cells isolated from BDC2.5 TCR Tg NOD mice (I-J) or CD8
+
 T cells isolated 
from 8.3 TCR Tg NOD mice (K-L) were cultured with BDC2.5 or IGRP peptides, respectively, in the 
presence of different concentrations of oATP or CE-224,535. Data are expressed as mean±standard error 
of the mean (SEM). Data are representative of at least n=3 mice. *P<0.05; **P<0.01; ***P<0.001. 
Abbreviations. wks (weeks of age); Nglc (normoglycemic); Hglc (hyperglycemic); H&E (hematoxylin 
and eosin); oATP (oxidized ATP). 
 
Figure 4. P2X7R blockade delays diabetes in NOD mice and reduces islet infiltration and the 
autoimmune response by CD8
+
 cells. (A-H) The effect of P2X7R blockade was tested in early (4-
week-old NOD mice) and late (10-week-old NOD mice) prevention studies in vivo using (i) oATP, (ii) 
CE-224,535, and (iii) a combination of oATP or CE-224,535 with clinical-grade-dose Rapamycin. The 
treatment with oATP and oATP plus Rapamycin, but not with CE-224,535 alone or with Rapamycin, 
significantly delayed the onset of diabetes in the early prevention study setting as compared to untreated 
animals (A, B); data are representative of n=10 mice per group. In the late prevention study, while oATP 
and CE-224,535 alone did not show any effect on the onset of diabetes (E and G), their combination 
with Rapamycin successfully delayed diabetes onset (F and H); data are representative of n=10 mice per 
group. (I,  J) Representative H&E staining and immunohistochemical analysis of pancreatic islet tissue 
sections from the different groups of treated and untreated NOD mice. (K and L) Semi-quantitative 
analysis of islet infiltrate in 4-week-old treated NOD mice revealed that oATP+Rapamycin is more 
effective in reducing islet infiltration, although it is associated with an overall reduced number of islets. 
(M, N) CD4
+
CD25
-
 and CD8
+
 T cells isolated from the spleens of 10-week-old treated and untreated 
NOD mice and cultured in the presence of BDC2.5 or IGRP peptides respectively showed a reduced 
number of IFN-γ
+
 CD8
+
, but not CD4
+
, T cells in mice treated with oATP alone or in combination with 
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Rapamycin as compared to untreated mice. (O) The pancreata of 10-week-old normoglycemic P2X7R
-/-
 
and WT NOD mice contain P2X7R mRNA. (P) mRNA expression of P2X1R, P2X2R, P2X4R, P2X5R 
and P2X7R in splenic CD4
+
CD25
-
 cells were significantly increased in P2X7R
-/-
 NOD mice as 
compared to WT NOD mice; (Q) Western blot analysis of P2X1R, P2X4R and P2X7R in splenic 
CD4
+
CD25
- 
T cells
 
confirmed the absence of P2X7R protein in P2X7R
-/-
 NOD mice as compared to WT 
NOD mice. (R) mRNA expression of P2X1R, P2X4R, P2X5R and P2X7R in splenic CD4
+
CD25
-
 and in 
CD8
+
 T cells (except for P2X2R) were significantly increased in P2X7R
-/-
 NOD mice as compared to 
WT NOD mice; (S) Western blot analysis of P2X1R, P2X4R and P2X7R in splenic CD8
+
 T cells
 
confirming the absence of P2X7R protein in P2X7R
-/-
 NOD mice as compared to WT NOD mice. Data 
are expressed as mean±standard error of the mean (SEM). Data are representative of at least n=3 mice. 
*P<0.05; **P<0.01; ***P<0.001. 
Abbreviations. H&E (hematoxylin and eosin); oATP (oxidized ATP); Rapa (Rapamycin); A.U. 
(Arbitrary Units). 
 
Figure 5. Characterization of P2X7R
neg
 and P2X7R
pos
 cells reveals dependence of CD8 T cells on 
eATP/P2X7R signaling. (A-D) P2X7R
neg
 CD4
+
CD25
-
/CD8
+
 T cells isolated from 10-week-old 
hyperglycemic or normoglycemic NOD or BDC2.5/8.3 TCR Tg NOD mice (n=3 samples per group) 
showed no surface expression of P2X7R, while significant intracellular expression was detected. (E, F) 
The percentage of P2X7R
neg
 CD4
+
CD25
-
 T cells migrating to SDF-1 was significantly higher as 
compared to P2X7R
pos
 CD4
+
CD25
-
 T cells, while the opposite was observed in CD8
+
 T cells, with a 
higher percentage of migrating P2X7R
pos
 CD8
+
 T cells as compared to P2X7R
neg
 CD8
+
 T cells. (G, H) 
P2X7R
pos
 CD4
+
CD25
-
/CD8
+
 T cells from hyperglycemic NOD mice cultured with the CD4-/CD8-
restricted islet mimotope peptides BDC2.5 and IGRP, respectively, generated more IFN-γ
+
 T cells. (I 
and K) Higher OCR in basal conditions and after FCCP addition was observed in P2X7R
neg
 CD4
+
CD25
-
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T cells as compared to P2X7R
pos
 CD4
+
CD25
-
 T cells. (J and L) In P2X7R
pos
 CD8
+
 T cells, OCR was 
increased after FCCP addition and reduced in response to rotenone/antimycin A as compared to 
P2X7R
neg
 CD8
+
 T cells. While the maximal respiration capacity and SRC of P2X7R
pos
 CD8
+
 T cells 
were significantly increased, following addition of oligomycin and in response to rotenone/antimycin A, 
the OCR was significantly reduced as compared to P2X7R
pos
 CD8
+
 T cells. (M-P) P2X7R
neg
 
CD4
+
CD25
-
/CD8
+
 T cells from NOD.BDC2.5 and NOD.8.3 mice showed significant intracellular 
P2X7R expression as well. (Q, R) Among CD4
+
CD25
-
 T cells from NOD.BDC2.5 mice, the percentage 
of migrating P2X7R
neg
 cells was significantly higher as compared to P2X7R
pos
 cells, while among CD8
+
 
T cells from NOD.8.3 mice, the percentage of P2X7R
pos
 cells migrating was higher as compared to 
P2X7R
neg
 cells. (S, T) Among both CD4
+
CD25
-
 and CD8
+
 T cells, the number of IFN-γ
+
 T cells 
generated during an islet peptide-based autoimmune assay was significantly higher among P2X7R
pos
 as 
compared to the P2X7R
neg
 cells. (U and W) Among CD4
+
CD25
-
 T cells from NOD.BDC2.5 mice, an 
increase in OCR was observed in P2X7R
pos
 cells in basal conditions and after FCCP injection as 
compared to P2X7R
neg
 cells. Among CD4
+
CD25
-
 T cells from NOD.BDC2.5 mice, the basal, maximal 
respiration and ATP-related OCR were significantly increased in P2X7R
pos
 as compared to P2X7R
neg
 
cells. (V and X) Among CD8
+
 T cells from NOD.8.3 mice, OCR was increased in basal conditions and 
after FCCP injection in P2X7R
neg
 as compared to P2X7R
pos
 cells. Among CD8
+
 T cells from NOD.8.3 
mice, the basal, maximal respiration, SRC and ATP-related OCR increased in P2X7R
neg 
as compared to 
P2X7R
pos
 cells. Data are expressed as mean±standard error of the mean (SEM). Data are representative 
of at least n=3 mice. *P<0.05; **P<0.01; ***P<0.001. 
Abbreviations. OCR (oxygen consumption rate); FCCP (carbonyl cyanide p-trifluoromethoxyphenyl 
hydrazone); SRC (spare respiratory capacity). 
 
Figure 6. The novel recombinant protein sP2X7R containing the extracellular P2X7R domain 
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reduces the in vitro autoimmune response. (A, B) A schematic representation of the sequence and 
domain arrangements of human P2X7R and sP2X7R. (C) SDS-PAGE of sP2X7R after purification by 
gel filtration and staining with Coomassie blue is shown. (D, E) CD4
+
CD25
-
 and CD8
+
 T cells isolated 
from hyperglycemic NOD mice were cultured with the BDC2.5 and the IGRP peptides respectively; 
1µM sP2X7R reduces the number of IFN-γ
+
CD8
+
, but not CD4
+
, T cells. (F, G) CD4
+
CD25
-
 and CD8
+
 
T cells isolated from NOD.BDC2.5/8.3 mice were cultured with BDC2.5 and IGRP peptides and 
sP2X7R. sP2X7R reduces the number of IFN-γ
+
CD4
+
/CD8
+
 T cells dose-dependently. (H, I) Metabolic 
profile of CD8
+
 T cells at steady state and during an autoimmune response with or without sP2X7R. T 
cells cultured with sP2X7R showed higher OCR at basal and after FCCP as compared to controls. Basal 
and non-mitocondrial respiration as well as ATP production levels were higher in cells cultured with 
sP2X7R as compared to controls. (J) Working hypothesis summarizing the role of the eATP/P2X7R axis 
in the onset of T1D and the effects of the novel sP2X7R recombinant protein. Data are expressed as 
mean±standard error of the mean (SEM). Data are representative of at least n=3 mice. *P<0.05; 
**P<0.01; ***P<0.001. 
Abbreviations. sP2X7R (soluble P2X7R); OCR (oxygen consumption rate); FCCP (carbonyl cyanide p-
trifluoromethoxyphenyl hydrazone). 
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Figure S1. (A) Representative dot plots for P2X7R isotype antibody staining with CD4, CD45RO and 
CCR7 on human PBMCs are shown, depicting the gating strategy used in Fig. 1D-R. (B) Luminescence 
signal from pancreas harvested from pmeLUC transgenic mice and cultured in the presence of different 
glucose concentrations (5, 25 and 50mM) was quantified as photons/second. (C) Bar graph depicting 
eATP release by the human β cell line Beta-lox5 cultured in high glucose or in the presence of IFN-γ (2 
ng/ml) and IL-1β (1,000 U/ml) (n=3 samples per group). (D) Bar graph depicting eATP release by the 
Caco-2 cell line cultured in high glucose or in the presence of IFN-γ (2 ng/ml) and IL-1β (1,000 U/ml) 
(n=3 samples per group). (E) Bar graph depicting eATP release by human PBMCs from T1D patients 
cultured in the presence of Diftavax or anti-CD3 and CD28 (n=3 samples from each group). (F) Isolated 
CD8
+
 T cells from healthy controls were challenged with antigen vaccines (Diftavax) in the presence or 
absence of P2X7R antagonists oATP or CE-224,535.  
 
Abbreviations. PBMCs (peripheral blood mononuclear cells). 
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Figure S2. (A, B) Representative H&E staining and immunohistochemical analysis of CD3 and P2X7R 
expression on pancreatic islet tissue sections of hyperglycemic NOD mice. (C, D) P2XsR mRNA levels 
were quantified on splenic CD4
+
CD25
-
 and CD8
+
 isolated T cells from 4- and 10-week-old and 
hyperglycemic NOD mice, normalized to levels of GAPDH and expressed as fold increase compared to 
10-week-old normoglycemic NOD mice. (E, F) Splenocytes from hyperglycemic NOD mice were 
cultured with the CD4/CD8-restricted islet mimotope peptides BDC2.5/IGRP respectively or with 
GAD65 and insulin, in the presence of different concentrations of BzATP (5, 50, 500µM) in an IFN-γ 
ELISpot assay. High levels of BzATP induced apoptosis of splenocytes as determined by staining for 
AnnexinV and 7-AAD by flow cytometric analysis. (G, H) CD4
+
CD25
-
 T cells cultured in the presence 
of different concentrations of ATP showed a slight but significant upregulation of P2X7R expression on 
CD4
+
CD25
-
 T cells, while in CD8
+
 T cells, P2X7R was markedly upregulated, particularly following 
treatment with 50 µM ATP. 
Abbreviations. H&E (hematoxylin and eosin); GAPDH (glyceraldehyde-3-phosphate dehydrogenase); 
BzATP (Benzoyl-ATP); eATP (extracellular ATP); 7-AAD (7-amino-actinomycin D). 
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Figure S3. (A-E) The effect of P2X7R blockade was tested in a reversal study using (i) oATP, (ii) CE-
224,535, or (iii) a combination of oATP or CE-224,535 with clinical-grade-dose Rapamycin, and 
Rapamycin alone. (F-G) Extracellular acidification rate (ECAR) measurements of CD8
+
P2X7R
pos
 and 
CD8
+
P2X7R
neg
 isolated from 10-week-old NOD normoglycemic mice indicate diminished capacity of 
CD8
+
P2X7R
neg
 to mount a glycolytic response.  
 
Abbreviations. eATP (extracellular ATP); oATP (oxidized ATP); 2-DG (2-deoxy-D-glucose). 
. 
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Figure S4. (A-D) Representative flow cytometric analysis and quantitative bar graphs for CD38
+
CD4
+
 T 
cells (A, B) and CD38
+
CD8
+
 T cells (C, D) in splenocytes of P2X7R
-/-
 NOD and WT NOD mice.  
Abbreviations. WT (wild type); NOD (non-obese diabetic). 
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Figure S5. (A-B) The immunosuppressive ability of P2X7R
pos
 versus P2X7R
neg
 Tregs was studied in an 
ELISpot assay in which CD4
+
CD25
-
 TCR tg naïve T cells isolated from NOD BDC2.5 Tg mice were 
stimulated with BDC2.5 peptides and challenged in a dose-dependent manner (with ratios of 1:1, 1:5, or 
1:10 of Tregs to T cells, using either P2X7R
pos
 or P2X7R
neg
 Tregs). (C) The cytokine profiles of 
P2X7R
pos
 versus P2X7R
neg
 Tregs were examined by flow cytometric analysis. (D) Oxygen consumption 
rate (OCR) measurements using P2X7R
pos
 versus P2X7R
neg
 Tregs, in which cells were subjected to 1µM 
oligomycin, which inhibits ATP synthase and limits mitochondrial OCR. Subsequently, FCCP (cyanide-
4-[trifluoromethoxy]phenylhydrazone), which uncouples mitochondrial respiration and maximizes OCR, 
was added (0.5 µM). (E) Basal respiration and maximal respiration of the P2X7R
pos
 versus P2X7R
neg
 
Treg subsets are shown. (F, H) The effect of BzATP on iTreg generation was determined by assessing 
Foxp3 expression in an apoptosis assay (G); the cytokine profile of iTregs following ex vivo challenge 
with BzATP was also determined by flow cytometry (I). 
 
Abbreviations. WT (wild type); NOD (non-obese diabetic); BzATP, Benzoyl adenosine triphosphate; 
Tregs, T regulatory cells; iTregs, induced T regulatory cells. 
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Video S1. Video showing the mechanism of action of sP2X7R. 
Abbreviations. sP2X7R (soluble P2X7R). 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Murine in vivo imaging 
In vivo bioluminescent imaging was performed with an ultra-low noise, high sensitivity cooled CCD 
camera mounted on a light-tight imaging chamber (IVIS Lumina System, Caliper, PerkinElmer, 
Waltham, USA). Tracking, monitoring and quantification of signals were controlled by the acquisition 
and analysis software Living Image (PerkinElmer). NOD and BALB/c mice at 4, 8, 10 and 14 weeks of 
age were inoculated i.p. with 2x10
6
 HEK-pmeLUC cells. After cell inoculation, 150 mg/kg (3 
mg/mouse) of D-Luciferin (Promega, Madison, WI) was administered i.p. to anesthetized mice with 2% 
isoflurane 15 minutes before image acquisition. The luminescent signal was captured from ventral view, 
and Regions Of Interest (ROI) from displayed images were identified and quantified as total 
photons/second using the Living Image software. This ATP probe or plasma membrane luciferase 
(pmeLUC) is a chimeric protein previously generated by engineering a firefly luciferase-folate receptor 
chimeric protein that retains the N-terminal leader sequence and the C-terminal GPI anchor of the folate 
receptor. Due to the folate receptor leader sequence, pmeLUC is targeted to the plasma membrane and 
detects ATP in the extracellular milieu close to the cell surface. pmeLUC is sensitive to ATP in the low 
micromolar to millimolar level, while it is insensitive to all other nucleotides
5
. After 15 minutes 
following injection, luminescence levels were assessed using an IVIS-Caliper luminometer in the 
pancreas projection on the abdominal wall. 
Murine interventional studies 
Mice were injected i.p with oATP alone, CE-224,535 alone or in combination with Rapamycin (LC 
Laboratories, Woburn, MA) according to the following therapy protocols: (i) oATP: 8 mg/kg/day i.p. for 
4 weeks, (ii) Rapamycin: 0.1 mg/day for 10 days, (iii) oATP+Rapamycin: combination of (i) and (ii), 
(iv) CE-224,535 0.2mg/kg i.p. for 4 weeks, (v) CE-224,535+Rapamycin: combination of (iv) and (ii). 
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oATP, Benzoyl-ATP (BzATP; Sigma-Aldrich) and CE-224,535 were used in in vitro assays as well. 
In vitro imaging 
For in vitro imaging, pancreata from female pmeLUC transgenic mice were collected and incubated for 
1 minute at 37°C in Petri dishes containing PBS supplemented with 5 mM glucose. Each pancreas was 
then transferred to Petri dishes containing 1 ml of PBS supplemented with 5 mM, 25 mM or 50 mM 
glucose at 37°C. 150 µg/dish of D-luciferin (Promega) were added, and the imaging signal was acquired 
immediately after using the IVIS system.   
Islet culture 
Pancreatic islets were isolated from NOD mice using the collagenase digestion method, as described 
previously
6
. Islets were cultured at 37 °C in a humidified, 5% CO2 atmosphere in RPMI 1640 medium 
(Gibco BRL, Grand Island, NY) supplemented with 10% fetal bovine serum, 2 mM glutamine for 24 or 
72h. Murine recombinant IL-1β
7
, IFN-γ
7
, IL-8
8
, and TNF-α were obtained from R&D Systems.  
ELISA 
Bioluminescent detection of ATP levels was performed on both human and murine islet culture 
supernatants, on serum samples from NOD mice at 4 and 10 weeks of age, on serum obtained from 
hyperglycemic NOD mice, and on supernatant collected after human ELISpot assays using the Enliten 
ATP assay system (FF2000, Promega) as reported previously
9
. ATP measurements were then performed 
using a luminometer (Berthold Technologies, Oak Ridge, TN).  
Murine antibodies 
The following antibodies were used for flow cytometric analysis in this study: PE-conjugated anti-mouse 
CD25, -anti-mouse CD44, -anti-mouse P2X7R, peridin-chlorophyll-protein complex-conjugated anti-
mouse CD11c, APC-labeled anti-mouse CD4, anti-mouse CD8, anti-mouse CD62L, anti-mouse CD19, 
and anti-mouse Foxp3 were purchased from BD Biosciences, eBioscience or BioLegend (San Diego, 
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CA). FITC-conjugated anti-mouse P2X7R was purchased from Alomone Labs. Apoptosis was assessed 
with the Annexin V Apoptosis Detection Kit I purchased from BD Biosciences, and was analyzed as 
previously described
10
.  
Murine flow cytometric analysis 
To characterize P2X7R expression, murine splenic cells were double-stained with anti-mouse P2X7R 
and anti-mouse CD4, CD8, CD19 or CD11c. CD4 or CD8 effector T cells were determined by triple 
staining with CD4 or CD8, anti-mouse CD44 and CD62L, respectively. Regulatory T cells were 
identified by staining for CD4, anti-mouse CD25, and upon permeabilization using the 
Fixation/Permeabilization kit (eBioscience) for anti-mouse Foxp3. A FACSCalibur flow cytometer 
(Becton Dickinson) was used to analyze cells with light scatter properties of lymphocytes. Background 
staining was determined using nonreactive isotype-matched control mAbs with gates positioned to 
exclude 99% of non-reactive cells. FlowJo software version 8.7.3 (Treestar, Ashland, OR) was used to 
analyze the data. 
In vitro stimulation of T cells 
To test the effect of T cell stimulation on the expression of P2X7R, CD4
+
 CD25
- 
T cells were isolated 
from murine splenic cells using the CD4
+
CD25
+
 Regulatory T cell Isolation Kit (Miltenyi Biotec, 
Auburn, CA). 5x10
5
 CD4
+
CD25
- 
T cells were cultured in a 96-well plate for 24 hours in the presence of 
IL-1β, IL-6, TNF-α or MCP-1 at concentrations of 1 or 10 ng/ml (R&D Systems), BzATP and ATP at 
concentrations of 5, 50 or 500 µM (Sigma-Aldrich), anti-mouse IFN-γ, anti-mouse IL-4, anti-mouse IL-
17 at concentrations of 1 or 10 µg/ml (BD Biosciences), oATP (Medestea srl, Turin, Italy) and CE-
224,535 (Pfizer, New York, NY) at concentrations of 1, 10 or 100 µM. After 24 hours cells were 
collected and stained with anti-mouse CD4 and anti-mouse P2X7R.  
Murine iTreg generation 
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CD4
+
 Treg differentiation was evaluated by culturing 2.5x10
5
 naive CD4
+
CD25
-
 T cells with plate-
bound anti-CD3 and soluble anti-CD28 (both at 1 µg/ml) in RPMI1640 media (Lonza, Walkersville, 
MD) supplemented with 10% FBS (Sigma-Aldrich), 2 mM L-glutamine, 1 mM sodium pyruvate, 0.75 
g/L sodium bicarbonate, 100 U/ml penicillin/streptomycin, 0.1 mM non-essential amino acids (all from 
Lonza) for 2 days with murine TGF-β1 (2 ng/ml), and murine IL-2 (10 ng/ml) at 37°C. After 2 days, 10 
ng/ml of murine IL-2 was added to iTreg cultures and incubated an additional 2 days.  
Murine apoptosis assay 
Differentiated iTregs cultured in the presence or absence of 5, 50, or 500 µM of Benzoyl-ATP (BzATP; 
Sigma-Aldrich) were collected and washed twice with cold PBS and then resuspended in 1x Binding 
Buffer (component no. 51-66121E; BD Biosciences) at a concentration of 5x10
5
 cells/ml. 100 µl of this 
solution  was transferred into a 5 ml culture tube and was stained with 5 µl of APC Annexin V and 5 µl 
7-AAD, followed by incubation for 15 min at RT (25°C) in the dark. After incubation, 400 µl of 1x 
Binding Buffer was added to each tube prior to acquisition on the flow cytometer. We used the following 
controls as recommended by the manufacturer in order to perform compensation and gating: unstained 
cells, cells stained with APC Annexin V (no 7-AAD) and cells stained with 7-AAD (no APC Annexin 
V).  
Murine ELISpot assay 
An ELISPOT assay was used to measure the number of IFN-γ-producing cells according to the 
manufacturer’s protocol (BD Biosciences) as previously performed by our group 
2
. To test the role of 
eATP/P2X7R-driven immunity on the autoimmune response, we used an islet-peptide based ELISpot 
assay. 1x10
6
 splenocytes isolated from hyperglycemic NOD mice were cultured in a microwell plate 
(BD Biosciences) coated with IFN-γ capture antibody (Ab) in the presence of the following islet 
peptides: BDC2.5 mimotope, IGRP (corresponding to residues 206 to 214 of murine islet-specific 
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glucose-6-phosphatase catalytic subunit-related protein), GAD (corresponding to residues 206 to 220 of 
the glutamic acid decarboxylase GAD65) and insulin (Anaspec [Fremont, CA] and Sigma Aldrich 
respectively) for 24 hours. oATP or CE-224,535 at concentrations of 1, 10 or 100 µM, BzATP at 
concentrations of 5, 50 or 500 µM, or sP2X7R at concentrations of 0.01, 0.01 or 1 µM were also added 
to the culture. After 24 hours, bound secondary Ab was visualized using HRP-streptavidin and the AEC 
substrate kit (BD Biosciences). Spots were counted using an Immunospot analyzer (Cellular Technology 
Ltd., Cleveland, OH) and expressed as the number of cytokine-producing spots per 1x10
6
 cells. 
Alternatively, CD4
+
CD25
-
, CD8
+
 T cells, and CD11c
+
 cells were isolated using the Regulatory T cell 
Isolation kit, the CD8a
+
 T cell Isolation kit or CD11c MicroBeads (Miltenyi Biotec), respectively. 5x10
5
 
CD4
+
CD25
-
 or CD8
+
 T cells were cultured with 2.5x10
5
 CD11c
+
 in the presence of BDC2.5 mimotope 
or IGRP peptide, respectively. After 24h, ELISpot plates were developed as described. P2X7R
-
 and 
P2X7R
+
 CD4
+
CD25
-
 or CD8
+
 T cells were selected by staining freshly-isolated CD4
+
CD25
-
 or CD8
+
 T 
cells with PE-conjugated anti-mouse P2X7R antibody, followed by incubation with anti-PE microbeads 
for selection (Miltenyi Biotec). 2.5x10
5
 P2X7R
-
 or P2X7R
+
 CD4
+
CD25
-
/CD8
+
 T cells were co-cultured 
with 1.25x10
5
 CD11c
+
 cells and BDC2.5 or IGRP, respectively. After 24h, ELISpot plates were 
developed, or cells were collected and P2X7R expression was assessed by flow cytometry, as described. 
Histopathology and immunohistochemistry 
Immunohistochemistry was performed with 5 µm-thick formalin-fixed, paraffin-embedded pancreatic 
tissue sections as described previously 
6
. Photomicrographs (400x or 200x) were taken using an 
Olympus BX41 microscope (Center Valley, PA). The following primary antibodies were used: anti–CD3 
(Cell Marque, Rocklin, CA), anti–Foxp3 (eBioscience), anti-insulin (Dako North America, Carpinteria, 
CA) and anti-P2X7R (Alomone Labs). Graft histology was evaluated by an expert pathologist and was 
quantified as follows: (i) Insulin staining: 0: no insulin staining, 1: presence of scattered insulin-positive 
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cells, 2: presence of insulin-positive cell aggregates, 3: presence of preserved insulin-positive islets; (ii) 
Islet cell infiltrate: 0: no cell infiltrate, 1: presence of cell infiltrate around graft islets, 2: presence of cell 
infiltrate inside graft islets, 3: presence of cell infiltrate throughout the graft area without preserved islet 
structure. 
Confocal microscopy 
All immunofluorescence samples were observed using a confocal system (LSM 510 Meta scan head 
integrated with the Axiovert 200 M inverted microscope; Carl Zeiss, Jena, Germany) with an 63x oil 
objective. The images were acquired in multi track mode, using consecutive and independent optical 
pathways
11
. The number of CD3
+
/P2X7R
+
 cells was assessed by counting the number of orange-stained 
elements (the result of green and red signal super-imposition) in 10 histological fields at x63, 
respectively. 
Quantitative real-time PCR 
Total RNA was extracted from CD4
+
CD25
-
, CD8
+
 isolated T cells or from whole pancreas after 
homogenization. RNA was purified using an RNeasy kit (Qiagen, Valencia, CA) and was reverse-
transcribed into cDNA using Superscript III (Invitrogen, Carlsbad, CA). Transcripts were amplified 
using a 7300 Real-Time PCR System and primers from Applied Biosystems (Foster City, CA), 
normalized to copies of GAPDH and quantified by comparison to 10-week-old NOD mice. NOD-
P2X7R knock out RNA was isolated from pancreatic tissue sections and reverse-transcribed into cDNA 
as described. Amplified transcripts were normalized to GAPDH and number of islets, and quantified by 
comparison to 10-week-old NOD. 
Western blot 
Total protein of CD4
+
CD25
-
 T
 
cells samples were extracted using Laemmli buffer (Tris–HCl 62.5 
mmol/l, pH 6.8, 20% glycerol, 2% SDS, 5% β-mercaptoethanol), and their concentrations were 
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measured. 35 µg of total protein was electrophoresed on 7% SDS-PAGE gels and blotted onto 
nitrocellulose (Schleicher & Schuell, Dassel, Germany). Blots were then stained with Ponceau S. 
Membranes were blocked for 1 h in TBS (Tris [10 mmol/l], NaCl [150mmol/l]), 0.1% Tween-20, 5% 
non-fat dry milk, pH 7.4 at 25°C, and then incubated for 12 h with rabbit anti-P2X7R (Alomone Labs 
#APR-004), rabbit anti-mouse P2X7R (Alomone Labs #APR-008), rabbit anti-mouse P2X4 (Alomone 
Labs #APR-002), rabbit anti-mouse P2X1 (Alomone Labs #APR-001) or rabbit anti-mouse GAPDH 
(Cell Signaling, Danvers, MA) diluted in TBS–5% milk at 4°C. Membranes were washed three times 
with TBS–0.1% Tween-20, then incubated with a peroxidase-labeled anti-rabbit IgG antibody (ECL
TM
, 
#NA934) diluted 1:500 in TBS–5% milk, and finally washed with TBS–0.1% Tween-20. The resulting 
bands were visualized using enhanced chemiluminescence (SuperSignal; Pierce, Rockford, IL, USA). 
Finally, for the quantification of western blot bands, images of nitrocellulose membrane filters were 
analyzed by ImageJ software to quantify size and strength of protein bands. 
Migration assays 
Transwell migration assays were performed on isolated P2X7R
-
 or P2X7R
+
 CD4
+
CD25
-
 or CD8
+
 T cells 
in the presence of 0 to 50 ng/ml SDF-1 (R&D Systems). In brief, cells were suspended in 0.5% BSA 
Phenol Red-Free RPMI and plated in the upper chambers of an HTS-Transwell-96-well permeable 
support plate (Corning, Acton, MA). After overnight incubation, migrated cells were counted using BD 
TruCount (BD Biosciences) by flow cytometry.  
Metabolic assays 
We measured the bioenergetic function (oxygen consumption rate or OCR) of sorted P2X7R
-
 or P2X7R
+
 
CD4
+
CD25
-
 or CD8
+
 T cells using a XF24 and XF96 Extracellular Flux Analyzer (Seahorse Bioscience, 
North Billerica, MA). P2X7R
neg
 or P2X7R
pos
 CD4
+
CD25
-
 or P2X7R
neg
 or P2X7R
pos
 CD4
+
CD25
+
 or 
CD8
+
 T cells were resuspended in XF media (RPMI containing 25 mM glucose, 2 mM L-glutamine, and 
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1 mM sodium pyruvate adjusted to pH 7.4), and 4x10
5
 cells per well were plated in XF24 and XF96 
plates previously coated using CellTak (BD Biosciences) in order to enhance cell adherence. OCR 
measurements were assessed under basal conditions (3 measurements were taken) and in response to 2 
µM oligomycin, 1.5 µM fluoro-carbonyl cyanide phenylhydrazone (FCCP), and 1 µM rotenone + 1 µM 
antimycin A with the XF24 or XF96 analyzer (Seahorse Bioscience), at a rate of 3 measurements after 
injection of each compound. In another assay, we assessed glycolytic function (extracellular acidification 
rate, or ECAR) of sorted P2X7R
-
 or P2X7R
+
 CD8
+
 T cells. ECAR measurements were taken when cells 
were exposed to 10 mM glucose, 2 µM oligomycin and 50 mM of 2-Deoxy-D-glucose. 3 baseline 
measurements of ECAR were taken, and 3 measurements were taken after injection of each of the 3 
compounds (glucose, oligomycin and 2-Deoxy-D-glucose). 
Construction of the soluble P2X7R recombinant protein 
A construct encoding the fragment of human P2X7R containing amino acids 56-328 was amplified by 
PCR from P2X7R cDNA (NP_002553.3) using primers with the following sequences: 5’- 
CTGTATTTTCAGGGCGCCATGGATCCTGTCATCAGTTCTGTGCAC-3’ and 5’-
CTCTAGTACTTCTCGACAAGCTTCATCAAAATTTTCCTCCGGTGCCAAAAAC-3’. The 
amplified product was cloned into the pFHMSP-LIC-N donor plasmid, which is a derivative of the 
pFastBac HT A vector (Invitrogen) for directing secreted protein expression in insect cells via the 
Baculovirus Expression System. The pFHMSP-LIC-N vector has the Honeybee melittin signal sequence 
upstream of the poly-His tag and a SacB gene stuffer sequence subcloned between NcoI/HindIII 
restriction sites in the multiple cloning site sequence. The modified vector is supplied with a 26-amino 
acid N-terminal fusion tag containing 6X His followed by a TEV cleavage site, which are added in frame 
with the inserted coding sequence. The P2X7R 56-328 fragment was inserted into the cloning region of 
the NcoI/HindIII linearized pFHMSP-LIC-N using In-fusion (BD Biosciences) enzyme-mediated 
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recombination of complimentary DNA sequences that were inserted at the ends of the insert by 
engineered primer design and are present in the vector.  
Generation of recombinant Bacmid DNA and baculovirus 
DH10Bac E.coli cells (Invitrogen) were transformed with the recombinant donor vector pFHMSD-
P2X7R to generate recombinant viral DNA. Sf9 insect cells (Invitrogen) were transfected with the 
Bacmid DNA using Cellfectin reagent (Invitrogen), and recombinant baculovirus particles were 
recovered in the supernatant. The recombinant virus was sequentially amplified from P1 to P3 viral 
stocks before expression. 
Expression and purification of recombinant soluble P2X7R in insect cells 
Sf9 insect cells were grown in HyQ

 SFX Insect Serum Free Medium (GE Healthcare Life Sciences) 
infected with P3 viral stock, and cultured at 27°C on a shaker at 100 RPM. At day 4 post-infection, cell 
culture medium was collected, centrifuged at 14,000 g for 15 minutes, and the cell pellet discarded. The 
collected medium was neutralized adding 10x binding buffer (50 mM HEPES pH 7.5, 2400 mM NaCl, 
50 mM imidazole) and rocked with pre-equilibrated NiNTA beads. The resin was washed twice with two 
washing buffers (50 mM HEPES pH 7.5, 500 mM NaCl, 10 mM imidazole; 50 mM HEPES pH 7.5, 500 
mM NaCl, 40 mM imidazole). The bound protein was eluted with elution buffer (50 mM HEPES pH 7.5, 
500 mM NaCl, 250 mM imidazole) and loaded onto a Superdex 200 10/300GL gel filtration column (GE 
Healthcare, Boston, MA) equilibrated with 20 mM HEPES pH 7.5, 150 mM NaCl. The relevant 
fractions containing protein were pooled and concentrated by ultrafiltration using an Amicon Ultra-15 10 
kD MWCO filter unit (Millipore, Billerica, MA) to 2.4 mg/ml, with an overall yield of 2 mg/L.   
Statistical analysis 
Data are expressed as mean±standard error of mean. Kaplan-Meier analysis was used for analysis of 
survival. When 2 groups were compared, a two-sided unpaired Student t-test (for parametric data) or a 
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Mann-Whitney test (for non-parametric data) was used, according to distribution. A P value of less than 
0.05 (by two-tailed testing) was considered to be an indicator of statistical significance. Data and graphs 
were generated using GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA). 
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